Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2017

Open Access 01-12-2017 | Research article

Comparing Stent Thrombosis associated with Zotarolimus Eluting Stents versus Everolimus Eluting Stents at 1 year follow up: a systematic review and meta-analysis of 6 randomized controlled trials

Authors: Pravesh Kumar Bundhun, Chandra Mouli Yanamala, Wei-Qiang Huang

Published in: BMC Cardiovascular Disorders | Issue 1/2017

Login to get access

Abstract

Background

Two thousand fifteen has been a winning year for Drug Eluting Stents (DES). Increase in the number of patients with cardiovascular diseases treated by Percutaneous Coronary Intervention (PCI) has resulted to a high demand for second generation DES. This current analysis aimed to compare the different types of Stent Thrombosis (ST) associated with Zotarolimus Eluting Stents (ZES) versus Everolimus Eluting Stents (EES) at 1 year follow up.

Methods

Electronic databases were searched for studies comparing ZES with EES. Different types of ST reported at 1 year follow up were considered as the primary endpoints in this analysis. Odds Ratios (OR) with 95% Confidence Intervals (CIs) were used as the statistical parameters and the pooled analyses were carried out by the RevMan 5 · 3 software.

Results

A total number of 10,512 patients were included in this analysis. No significant difference in any definite ST, acute definite ST, subacute definite ST, and late definite ST were observed between ZES and EES, at 1 year follow up with OR: 1.70, 95% CI: 0.92 – 3.16; P = 0.09, OR: 3.44, 95% CI: 0.82 – 14.43; P = 0.09, OR: 1.13, 95% CI: 0.43 – 2.95; P = 0.80 and OR: 2.39, 95% CI: 0.83 – 6.85; P = 0.11 respectively. Moreover, any definite or probable ST and definite/probable/possible ST were also not significantly different with OR: 1.39, 95% CI: 0.89 – 2.17; P = 0.15 and OR: 1.19, 95% CI: 0.84 – 1.70; P = 0.33 respectively. In addition, any probable ST, acute probable ST, late probable ST and possible ST were also not significantly different at 1 year follow up with OR: 1.11, 95% CI: 0.60 – 2.05; P = 0.75, OR: 0.53, 95% CI: 0.12 – 2.40; P = 0.41, OR: 1.67, 95% CI: 0.35 – 7.86; P = 0.52 and OR: 1.08, 95% CI: 0.64 – 1.82; P = 0.78 respectively.

Conclusion

At 1 year follow up, ZES were not associated with significantly lower or higher definite and probable ST compared to EES. In addition, no significant difference was observed in acute, subacute and late definite or probable ST. However, further trials are recommended to assess the effects of these second-generation DES during the long-term.
Literature
1.
go back to reference Bundhun PK, Bhurtu A, Soogund MZ, Long MY. Comparing the clinical outcomes between drug eluting stents and bare metal stents in patients with insulin-treated type 2 diabetes mellitus: a systematic review and meta-analysis of 10 randomized controlled trials. PLoS ONE. 2016;11(4):e0154064.CrossRefPubMedPubMedCentral Bundhun PK, Bhurtu A, Soogund MZ, Long MY. Comparing the clinical outcomes between drug eluting stents and bare metal stents in patients with insulin-treated type 2 diabetes mellitus: a systematic review and meta-analysis of 10 randomized controlled trials. PLoS ONE. 2016;11(4):e0154064.CrossRefPubMedPubMedCentral
2.
go back to reference Bundhun PK, Wu ZJ, Chen MH. Is there any significant difference in stent thrombosis between sirolimus and paclitaxel eluting stents?: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95(5):e2651.CrossRef Bundhun PK, Wu ZJ, Chen MH. Is there any significant difference in stent thrombosis between sirolimus and paclitaxel eluting stents?: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95(5):e2651.CrossRef
3.
go back to reference Bundhun PK, Pursun M, Teeluck AR, Long MY. Are everolimus-eluting stents associated with better clinical outcomes compared to other drug-eluting stents in patients with type 2 diabetes mellitus?: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(14):e3276.CrossRef Bundhun PK, Pursun M, Teeluck AR, Long MY. Are everolimus-eluting stents associated with better clinical outcomes compared to other drug-eluting stents in patients with type 2 diabetes mellitus?: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(14):e3276.CrossRef
4.
go back to reference Qi-Hua L, Qi Z, Yu Z, et al. Long-term effect of second-generation drug-eluting stents for coronary artery disease, everolimus-elutingversus zotarolimus-eluting stents: a meta-analysis. Coron Artery Dis. 2015;26(3):259–65.CrossRefPubMed Qi-Hua L, Qi Z, Yu Z, et al. Long-term effect of second-generation drug-eluting stents for coronary artery disease, everolimus-elutingversus zotarolimus-eluting stents: a meta-analysis. Coron Artery Dis. 2015;26(3):259–65.CrossRefPubMed
5.
go back to reference Gu H, Hua K, Li W, Wang Y, Yang J. Safety and efficacy of everolimus-eluting stent versus zotarolimus-eluting stent: A meta-analysis of randomized controlled clinical trials and observational studies. Int J Cardiol. 2015;201:552–60.CrossRefPubMed Gu H, Hua K, Li W, Wang Y, Yang J. Safety and efficacy of everolimus-eluting stent versus zotarolimus-eluting stent: A meta-analysis of randomized controlled clinical trials and observational studies. Int J Cardiol. 2015;201:552–60.CrossRefPubMed
6.
go back to reference Cutlip DE, Windecker S, Mehran R, et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344–51.CrossRefPubMed Cutlip DE, Windecker S, Mehran R, et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344–51.CrossRefPubMed
7.
go back to reference Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Wiley, 2008:187-241. Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Wiley, 2008:187-241.
8.
go back to reference Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcareinterventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRefPubMedPubMedCentral Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcareinterventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRefPubMedPubMedCentral
9.
go back to reference Park KW, Lee JM, Kang SH, et al. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-elutingresolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries. J Am Coll Cardiol. 2013;61(5):536–44.CrossRefPubMed Park KW, Lee JM, Kang SH, et al. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-elutingresolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries. J Am Coll Cardiol. 2013;61(5):536–44.CrossRefPubMed
10.
go back to reference Lee JM, Youn TJ, Park JJ, et al. Comparison of 9-month angiographic outcomes of Resolute zotarolimus-eluting and everolimus-eluting stentsin a real world setting of coronary intervention in Korea. BMC Cardiovasc Disord. 2013;13:65.CrossRefPubMedPubMedCentral Lee JM, Youn TJ, Park JJ, et al. Comparison of 9-month angiographic outcomes of Resolute zotarolimus-eluting and everolimus-eluting stentsin a real world setting of coronary intervention in Korea. BMC Cardiovasc Disord. 2013;13:65.CrossRefPubMedPubMedCentral
11.
go back to reference Poorhoseini HR, Kassaian SE, Hoseini K, et al. Comparing clinical outcomes for a twelve-month trial of zotarolimus- and everolimus-eluting stents in patientswith coronary artery disease: data from the THCRIC registry. Ther Adv Cardiovasc Dis. 2016;10(4):206-13. Poorhoseini HR, Kassaian SE, Hoseini K, et al. Comparing clinical outcomes for a twelve-month trial of zotarolimus- and everolimus-eluting stents in patientswith coronary artery disease: data from the THCRIC registry. Ther Adv Cardiovasc Dis. 2016;10(4):206-13.
12.
go back to reference Omar A, Torguson R, Kitabata H, et al. Long-term safety and efficacy of second-generation everolimus-eluting stents compared to other limus-elutingstents and bare metal stents in patients with acute coronary syndrome. Catheter Cardiovasc Interv. 2014;84(7):1053–60.CrossRefPubMed Omar A, Torguson R, Kitabata H, et al. Long-term safety and efficacy of second-generation everolimus-eluting stents compared to other limus-elutingstents and bare metal stents in patients with acute coronary syndrome. Catheter Cardiovasc Interv. 2014;84(7):1053–60.CrossRefPubMed
13.
go back to reference Akin I, Hochadel M, Abdel-Wahab M, Senges J, Richardt G, Schneider S, Tebbe U, Kuck KH, Nienaber CA. Clinical outcomes of different first- and second-generation drug-eluting stents in routine clinical practice: results from the prospective multicenter German DES.DE registry. Clin Res Cardiol. 2013;102(5):371–81.CrossRefPubMed Akin I, Hochadel M, Abdel-Wahab M, Senges J, Richardt G, Schneider S, Tebbe U, Kuck KH, Nienaber CA. Clinical outcomes of different first- and second-generation drug-eluting stents in routine clinical practice: results from the prospective multicenter German DES.DE registry. Clin Res Cardiol. 2013;102(5):371–81.CrossRefPubMed
14.
go back to reference D'Ascenzo F, Moretti C, Bianco M, et al. Meta-analysis of the duration of dual antiplatelet therapy in patients treated with second-generation drug-eluting stents. Am J Cardiol. 2016;117(11):1714–23.CrossRefPubMed D'Ascenzo F, Moretti C, Bianco M, et al. Meta-analysis of the duration of dual antiplatelet therapy in patients treated with second-generation drug-eluting stents. Am J Cardiol. 2016;117(11):1714–23.CrossRefPubMed
15.
go back to reference Lin L, Jin C, Wei X, et al. Comparison on the efficacy of everolimus-eluting stent and zotarolimus-eluting stents in coronary heartdisease between diabetic and non-diabetic patients. Int J Clin Exp Med. 2015;8(11):20813–20.PubMedPubMedCentral Lin L, Jin C, Wei X, et al. Comparison on the efficacy of everolimus-eluting stent and zotarolimus-eluting stents in coronary heartdisease between diabetic and non-diabetic patients. Int J Clin Exp Med. 2015;8(11):20813–20.PubMedPubMedCentral
16.
go back to reference Mehilli J, Richardt G, Valgimigli M, et al. ISAR-LEFT-MAIN 2 Study Investigators. Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol. 2013;62(22):2075–82.CrossRefPubMed Mehilli J, Richardt G, Valgimigli M, et al. ISAR-LEFT-MAIN 2 Study Investigators. Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol. 2013;62(22):2075–82.CrossRefPubMed
17.
go back to reference von Birgelen C, Sen H, Lam MK, et al. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring apercutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial. Lancet. 2014;383(9915):413–23.CrossRef von Birgelen C, Sen H, Lam MK, et al. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring apercutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial. Lancet. 2014;383(9915):413–23.CrossRef
18.
go back to reference Park KW, Kang SH, Kang HJ, et al. HOST–ASSURE Investigators. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-elutingstents & anti-platelet regimen), a randomized, controlled, noninferiority trial. J Am Coll Cardiol. 2014;63(25 Pt A):2805–16.CrossRefPubMed Park KW, Kang SH, Kang HJ, et al. HOST–ASSURE Investigators. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-elutingstents & anti-platelet regimen), a randomized, controlled, noninferiority trial. J Am Coll Cardiol. 2014;63(25 Pt A):2805–16.CrossRefPubMed
19.
go back to reference Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363(2):136–46.CrossRefPubMed Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363(2):136–46.CrossRefPubMed
20.
go back to reference von Birgelen C, Basalus MW, Tandjung K, et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol. 2012;59(15):1350–61.CrossRef von Birgelen C, Basalus MW, Tandjung K, et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol. 2012;59(15):1350–61.CrossRef
Metadata
Title
Comparing Stent Thrombosis associated with Zotarolimus Eluting Stents versus Everolimus Eluting Stents at 1 year follow up: a systematic review and meta-analysis of 6 randomized controlled trials
Authors
Pravesh Kumar Bundhun
Chandra Mouli Yanamala
Wei-Qiang Huang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2017
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-017-0515-4

Other articles of this Issue 1/2017

BMC Cardiovascular Disorders 1/2017 Go to the issue